

Shanghai Jahwa (600315 CH)

3Q largely in-line; FY earnings track well to the ESOP target

- **3Q results largely in line**, with revenue and net profits standing at RMB1.6bn (+1.2% YoY) and RMB156mn (+15.5% YoY). Consider a 4% YoY domestic revenue growth, total revenue increased by 3.5% YoY at constant exchange rate. The growth (vs a 23.8% decline for 2Q) was much underpinned by a 30% YoY growth in HPC revenue, which mitigated a 15%/5% decline in skincare/ Babycare revenue. Of note, HPC recorded a 17.9% ASP uptake, followed by 10.3% in babycare. By channel, offline sales grew 6%.
- **Margins trajectories diverged.** GPM declined QoQ by 2.0pp to 54.3%, owing to higher contribution of lower-margins SKU. This is despite an average 5% lower input cost (mainly palm oil) that equivalent to a RMB400/ton procurement cost savings. That said, operation cost initiatives had brought down opex ratio of the quarter by 7.5pp to 45.6%, leading to a 3.2pp expansion in operating margins to 8.3%. With these, we continue to envisage 4Q margins trajectories to normalize, and the worst of Jahwa is behind us.
- **A lukewarm Double.11 expectation:** September social retail sales came in at 2.5% YoY growth to RMB377.5bn, below 2.9% of market consensus. Cosmetic sales was RMB31.7bn, down 3.1% YoY, with 9M sales declining 3% YoY. A softening consumption sentiment has prompted for a lower expectation of the upcoming Double.11, in our view. Of note, online cosmetic retailers reportedly expect a 5-10% YoY sales decline, according to our channel check and survey. Meanwhile, at the expense of Korean and US/European brands, we think domestic brands could gain market share by leveraging their hero product strategy.
- **Revised 2020 ESOP targets:** During 2Q results, Jahwa management has revised down the revenue/ net profits target for 2022-23E/ 2023E, respectively. The revised targets imply +10.2%~+24.7%/ -16.6%~+38.4% YoY revenue/ Net profits growth in 2H22 and -1.9%~4.6%/ -29.0%~+1.8% YoY revenue/ Net profits growth in 2022E. Management targets at least DD topline growth and higher bottom-line growth in 2H22, and an accelerated topline growth in 2023E.
- **Our current 2022E forecast is at par to the B Target of Jahwa's revised 2020 ESOP plan**, while that of 2023E is slightly below. We keep our earnings forecasts and TP for now. We value the shares at an unchanged 40x mid-23E P/E which represents mean valuation since 2019.

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	7,032	7,646	7,497	8,154	8,799
YoY growth (%)	(7.4)	8.7	(1.9)	8.8	7.9
Net income (RMB mn)	430	649	574	755	884
EPS (RMB)	0.6	1.0	0.8	1.1	1.3
YoY growth (%)	(23.0)	49.6	(11.5)	31.4	17.1
Consensus EPS (RMB)	n.a	n.a	1.1	1.4	1.7
P/E (x)	n.a	n.a	31.9	24.3	20.7
P/B (x)	n.a	n.a	2.5	2.3	2.2
Div yield (%)	0.6	0.9	0.9	1.2	1.4
ROE (%)	6.6	9.3	7.8	9.5	10.3
Net gearing (%)	net cash	net cash	net cash	net cash	net cash

BUY (maintain)

Target Price **RMB39.2**
 (Previous TP **RMB39.2**)
 Up/Downside **+44.1%**
 Current Price **RMB27.2**

China Consumer Staples - Household and Personal Care

Joseph Wong
 (852) 3900 0838
 josephwong@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	18,483.7
Avg 3 mths t/o (RMB mn)	109.7
52w High/Low (RMB)	48.34/ 26.82
Total Issued Shares (mn)	679.6

Source: Wind

Shareholding Structure

Shanghai Jiahua (Group) Co.	50.8%
Shanghai Jiushi Group Co.	3.9%
SH Chongyang Strategic Inv	2.8%


Source: Wind

Share Performance

	Absolute	Relative
1-mth	-5.1%	0.9%
3-mth	-21.3%	-8.5%
6-mth	-8.6%	-3.8%

Source: Wind

12-m Price Performance



Source: Wind

Related Reports


1. [Proya Cosmetics \(603605 CH\) – 3Q a small beat; but the implied 4Q numbers look unexciting given the current guidance](#) – 18 Oct 2022
2. [Jahwa \(600315 CH\) – 2Q miss; but the worst is likely behind us](#) – 22 Aug 2022
3. [China Cosmetics – The crown jewel of the consumption spectrum; initiate Botanee/ Proya/ Jahwa with Buy](#) – 21 Jun 2022

Source: Company data, Bloomberg, CMBIGM estimates


Figure 1: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	7,497	8,154	8,799	8,248	9,362	10,470	-9.1%	-12.9%	-16.0%
Gross Profits	4,379	4,855	5,345	4,960	5,712	6,480	-11.7%	-15.0%	-17.5%
EBIT	535	674	834	825	1,057	1,271	-35.1%	-36.2%	-34.4%
Net profits	574	755	884	756	954	1,135	-24.0%	-20.9%	-22.1%
Gross Margins	58.4%	59.5%	60.7%	60.1%	61.0%	61.9%	-1.7ppt	-1.5ppt	-1.1ppt
EBIT Margins	7.1%	8.3%	9.5%	10.0%	11.3%	12.1%	-2.9ppt	-3ppt	-2.7ppt
Net Margins	7.7%	9.3%	10.0%	9.2%	10.2%	10.8%	-1.5ppt	-0.9ppt	-0.8ppt


Source: Company data, CMBIGM estimates

Figure 2: China cosmetics sales and ytd growth


Source: Wind, CMBIGM

Figure 3: Quarterly revenue growth trajectories

Source: Company data, CMBIGM estimates

Figure 4: Jahwa - 12M forward P/E band

Source: Company data, Bloomberg, CMBIGM estimates

Figure 5: Jahwa - 12M trailing P/B band

Source: Company data, Bloomberg, CMBIGM estimates

Financial Summary

Income statement

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	7,032	7,646	7,497	8,154	8,799
Major business	7,028	7,638	7,489	8,146	8,791
Others	4	8	8	8	8
Gross profit	4,216	4,491	4,379	4,855	5,345
Tax and surcharges	(57)	(59)	(58)	(63)	(68)
Selling expenses	(2,924)	(2,947)	(2,871)	(3,123)	(3,370)
Administrative expenses	(721)	(791)	(765)	(832)	(898)
R&D expenses	(144)	(163)	(150)	(163)	(176)
EBIT	370	531	535	674	834
EBITDA	606	740	734	875	1,039
Finance costs, net	(43)	(13)	(9)	(9)	(10)
Other income/(expense)	207	234	150	224	217
Non-operating	0	12	-	-	-
Pre-tax profit	534	764	676	889	1,041
Income tax	(104)	(115)	(102)	(134)	(157)
Less: Minority interests	-	-	-	-	-
Net profit	430	649	574	755	884

Cash flow summary

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Net income	875	319	574	755	884
D&A	236	209	199	201	206
Change in working capital	3	100	(243)	(169)	(27)
Others	(470)	365	20	20	20
Net cash fr. operating act.	643	993	550	807	1,083
Capex & investments	(106)	(141)	(138)	(150)	(162)
Investments	(5,565)	(5,186)	(83)	(91)	302
Others	4,899	4,943	-	-	-
Net cash fr. investing act.	(772)	(384)	(221)	(241)	140
Dividend payment	(136)	(197)	(172)	(227)	(265)
Cash received from investment	132	47	-	-	-
Cash received from borrowing	1,068	-	-	-	-
Others	(1,200)	(79)	(100)	(100)	(100)
Net cash fr. financing act.	(136)	(228)	(272)	(327)	(365)
Net change in cash	(322)	311	57	240	858
Cash at the beginning of the year	1,609	1,287	1,597	1,654	1,894
Exchange difference	(58)	(71)	-	-	-
Cash at the end of the year	1,229	1,527	1,654	1,894	2,752
Less: pledged cash	-	-	-	-	-

Balance sheet

YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Non-current assets	5,140	5,365	5,387	5,427	5,480
PP&E/Fixed assets	1,019	939	970	1,010	1,057
Net intangibles	769	761	752	752	759
Goodwill	1,986	1,923	1,923	1,923	1,923
Other non-current assets	1,366	1,742	1,742	1,742	1,742
Current assets	6,155	6,780	7,114	7,522	8,042
Cash	1,287	1,597	1,654	1,894	2,752
Account receivable	1,090	1,109	1,232	1,340	1,446
Prepayments	47	83	83	83	83
Inventory	867	872	1,025	1,085	1,041
Other current assets	2,865	3,119	3,119	3,119	2,719
Current liabilities	2,876	3,210	3,243	3,242	3,277
Borrowings	-	-	-	-	-
Accounts payable	718	718	752	750	785
Other payables	1,607	1,790	1,790	1,790	1,790
Other current liabilities	551	701	701	701	701
Non-current liabilities	1,920	1,972	1,872	1,772	1,672
Borrowings	1,062	925	825	725	625
Deferred tax liabilities	99	123	123	123	123
Other non-current liabilities	759	924	924	924	924
Minority Interest	-	-	-	-	-
Total net assets	6,499	6,963	7,385	7,934	8,573
Shareholders' equity	6,499	6,963	7,385	7,934	8,573

Key ratios

YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Sales mix (%)	100.0	100.0	100.0	100.0	100.0
Skincare and cleanser	99.9	99.9	99.9	99.9	99.9
Makeup	0.1	0.1	0.1	0.1	0.1
P&L ratios (%)					
Gross margin	60.0	58.7	58.4	59.5	60.7
Operating margin	5.3	6.9	7.1	8.3	9.5
Pre-tax margin	7.6	10.0	9.0	10.9	11.8
Net margin	6.1	8.5	7.7	9.3	10.0
Effective tax rate	(19.4)	(15.1)	(15.1)	(15.1)	(15.1)
Balance sheet analysis					
Current ratio (x)	0.2	0.2	0.2	0.3	0.3
Net receivable days	57	53	60	60	60
Net payable days	93	83	88	83	83
Inventory turnover days	112	101	120	120	110
Net debt to equity (%)	net	net	net	net	net
Returns (%)					
ROE	6.6	9.3	7.8	9.5	10.3
ROA	3.8	5.3	4.6	5.8	6.5
Dividend yield	0.6	0.9	0.8	1.0	1.2
Per share					
EPS (RMB)	0.6	1.0	0.8	1.1	1.3
DPS (RMB)	0.2	0.3	0.3	0.3	0.4
BVPS (RMB)	9.7	10.3	10.9	11.6	12.5

Source: Company data, CMBIGM estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM

OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBIGMG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBIGMG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBIGMG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBIGMG at +65 6350 4400 for matters arising from, or in connection with the report.